Progress in the treatment of psoriasis is undeniable. However, not everything Griffiths and colleagues discuss has come to ...

Biosimilars show comparable safety with Humira among new users with psoriasis in a multinational cohort study, but ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

Psoriasis severity and systemic inflammation linked to cardiovascular disease: insights for better patient care.

Discover how immune checkpoint inhibitors, a revolutionary cancer therapy, increase psoriasis risk. Essential insights for ...

The study, published in JAMA Dermatology, revealed that psoriasis severity, measured by the Psoriasis Area and Severity Index ...

Researchers at the University of Copenhagen have developed an electrospun nanofibre patch for the easier and more effective ...

Johnson & Johnson has reported positive outcomes from its Phase III trial of oral icotrokinra for treating plaque psoriasis.

Results for icotrokinra (JNJ-2113) have shown the drug’s potential to offer significant relief for patients suffering from moderate-to-severe plaque psorias ...

Risankizumab had greater improvements in skin clearance and quality of life at 16 weeks in patients with psoriasis compared with deucravacitinib.

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily ...